PRO 140 single agent therapy is the first successful single agent therapy in the history of HIV for a sub-population of HIV Response rate for the company’s innovative PRO 140 nearly doubled after dosage increase About 70 percent of phase 3 trial participants treated with higher doses have achieved viral load suppression The monotherapy would […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.